Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine analysts that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $46.83.

DNTH has been the subject of a number of research analyst reports. Raymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating for the company.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $23.38 on Wednesday. The company has a 50-day simple moving average of $22.65 and a 200-day simple moving average of $24.97. The firm has a market capitalization of $691.98 million, a P/E ratio of -9.35 and a beta of 1.82. Dianthus Therapeutics has a 52 week low of $18.13 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC raised its position in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after purchasing an additional 1,124 shares in the last quarter. R Squared Ltd bought a new stake in Dianthus Therapeutics during the fourth quarter worth about $26,000. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the fourth quarter worth about $33,000. KBC Group NV bought a new stake in Dianthus Therapeutics during the fourth quarter worth about $35,000. Finally, BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics during the fourth quarter worth about $59,000. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads